Hera-MI is a 2017 French start-up based in Nantes and founded by Sylvie Davila. Most of Hera-MI's collaborators have more than 15 years of experience in medical imaging, clinical studies and medical device certification. Breast cancer is the leading cancer in terms of frequency and mortality in women. If detected early enough, the 5-year survival rate is 99%, whereas it is only 26% for metastatic cancer.
The main purpose of Hera-MI is to use AI to help early-stage breast cancer diagnosis in order to optimize patient care.
Our ambition is to speed up and improve breast cancer diagnosis thanks to the development of clinical decision support solutions.
Viewing this video may result in cookies being placed by the vendor of the
video platform to which you will be directed. Given the refusal of the
deposit of cookies that you have expressed, in order to respect your
choice, we have blocked the playback of this video. If you want to
continue and play the video, you must give us your consent by clicking on
the button below.
I accept - Launch the video
Viewing this video may result in cookies being placed by the vendor of the
video platform to which you will be directed. Given the refusal of the
deposit of cookies that you have expressed, in order to respect your
choice, we have blocked the playback of this video. If you want to
continue and play the video, you must give us your consent by clicking on
the button below.
